COMMUNIQUÉS West-GlobeNewswire

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth
21/01/2026
Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Mont-Saint-Guibert, Belgium – January 21, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: [...]
Axogen Announces Proposed Public Offering of Common Stock
21/01/2026
ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair
21/01/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has completed the acquisition of Integrity Orthopaedics, further strengthening its sports medicine shoulder repair business with [...]
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
21/01/2026
The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and Innovation TARRYTOWN, N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Society for Science (the Society) and [...]
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
21/01/2026
PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT MASITINIB HAS UNIQUE [...]
AB Science obtient un brevet japonais pour l'utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu'en 2041
21/01/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE OBTIENT UN BREVET JAPONAIS POUR L'UTILISATION DU MASITINIB DANS LE TRAITEMENT DES FORMES PROGRESSIVES DE LA SCLÉROSE EN PLAQUES (SEP) JUSQU'EN 2041 IL S'AGIT DU PREMIER PAYS À OCTROYER LE [...]
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
21/01/2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) Nantes, France, January 21, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today acknowledges [...]
OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101)
21/01/2026
OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101) Nantes, le 21 janvier, 18 heures - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo : OSE) prend [...]
IBA – TRANSPARENCY NOTIFICATION
21/01/2026
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, January 21, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world leader in [...]
IBA SA – NOTIFICATION TRANSPARENCE
21/01/2026
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 21 janvier 2026, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
21/01/2026
PARIS, FRANCE, 21 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim [...]
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
21/01/2026
The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and Innovation TARRYTOWN N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Society for Science (the Society) and [...]
CS Group (OTCQB: CSDX) Announces Multi-Channel Sales Model, Global Logistics Partners, and Sustainable Innovation Roadmap for MEDUSA SDP
21/01/2026
CHEYENNE, Wyo., Jan. 21, 2026 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX) today detailed its multi-channel sales strategy , global logistics partnerships , and sustainability roadmap supporting the commercial [...]
Alignment Healthcare Named to the 2026 Fortune World’s Most Admired Companies™ List for First Time
21/01/2026
In its first year of eligibility, award-winning Medicare Advantage company earns spot on global corporate reputation list, joining major corporations like Amazon and Apple ORANGE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE [...]
HNL Lab Medicine Expands Services with New Pocono Creek Patient Service Center Featuring Dedicated Pediatric Phlebotomy Space
21/01/2026
BARTONSVILLE, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine, a trusted leader in comprehensive laboratory testing services, is pleased to announce the opening of its newest Patient Service Center in [...]
FSR Announces $400,000 Investment in New Round of Cardiac and Pilot Grant Awards to Drive Breakthroughs in Diagnosis and Treatment of Sarcoidosis
21/01/2026
CHICAGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) has awarded four grants in the amount of $100,000 each to Dr. Christen Vagts from the University of Illinois at Chicago, Dr. Chieh [...]
Le tribunal arbitral confirme la résiliation par Ipsen de l'accord de R&D conclu avec Galderma
21/01/2026
PARIS, FRANCE, 21 janvier 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY) annonce que le Tribunal arbitral de la Chambre de commerce internationale (CCI) a rendu une décision finale en faveur d'Ipsen, rejetant la demande [...]
NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts
21/01/2026
BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and [...]
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
21/01/2026
– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE [...]

Pages